Abstract
The management of infections with New Delhi metallo-beta-lactamase-1 (NDM)-producing bacteria remains clinically challenging given the multidrug resistant (MDR) phenotype associated with these bacteria. Despite resistance in vitro, ceftazidime-avibactam previously demonstrated in vivo activity against NDM-positive Enterobacteriaceae. Herein, we observed in vitro synergy with ceftazidime-avibactam and aztreonam against an MDR Klebsiella pneumoniae harboring NDM. In vivo, humanized doses of ceftazidime-avibactam monotherapy resulted in >2 log10 CFU bacterial reduction; therefore, no in vivo synergy was observed.
Original language | English (US) |
---|---|
Article number | e00486 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 61 |
Issue number | 7 |
DOIs | |
State | Published - Jun 2017 |
Externally published | Yes |
Keywords
- Ceftazidime-avibactam
- Klebsiella pneumoniae
- New Delhi metallo-β-lactamase
- Resistance
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases